Orion Corporation Announces Share Conversion
In an important update, Orion Corporation has recently announced that 71,498 A shares have been converted into B shares. This decision aligns with the company's Articles of Association, demonstrating a strategic move towards optimizing share distribution. The official entry of this conversion has been logged in the Trade Register.
New Share Structure Following Conversion
Following the conversion, the total number of shares for Orion Corporation stands at 141,134,278. This includes 31,770,319 A shares and 109,363,959 B shares. The company now has a total voting power of 744,770,339 across its shares, which strengthens its market presence.
Leadership Standing Behind the Move
The leadership team of Orion Corporation is committed to ensuring transparency and growth for its investors. The President and CEO, Liisa Hurme, along with General Counsel Mikko Kemppainen, are driving strategic initiatives such as this share conversion.
Contact Information for Investor Inquiries
For any inquiries regarding the recent changes or general investor relations, you can reach out to Tuukka Hirvonen, the Head of Investor Relations. He is available at +358 10 426 2721, ensuring that stakeholders receive timely information and support.
A Glimpse into Orion Corporation
Orion Corporation stands as a leading Nordic pharmaceutical company with a rich history spanning over a century. They specialize in the development, manufacturing, and marketing of both human and veterinary pharmaceuticals, including active pharmaceutical ingredients. Their impressive portfolio features a mix of proprietary and generic medicines, as well as consumer health products.
Focus on Core Therapeutic Areas
The company’s commitment to research and development focuses primarily on oncology and pain management, resulting in innovative treatments for cancer and neurological diseases, among others. In the previous year, Orion recorded net sales of EUR 1,542 million, and with a skilled workforce of about 3,700 professionals, they are dedicated to enhancing health and wellness on a global scale. Orion's shares are actively traded on Nasdaq Helsinki under the ticker ORNBV.
Frequently Asked Questions
What does the share conversion mean for investors?
The conversion of A shares to B shares signifies a restructuring that may affect voting rights and influence market dynamics.
How many total shares are there after the conversion?
After the conversion, Orion Corporation has a total of 141,134,278 shares.
Who can investors contact for more information?
Investors can contact Tuukka Hirvonen, Head of Investor Relations, at +358 10 426 2721.
What are Orion's main therapeutic areas?
Orion's core therapeutic areas include oncology and pain management, focusing on innovative treatments for various conditions.
How can I find more about Orion's financial performance?
For detailed information regarding financial performance and corporate developments, refer to their official communications or investor relations.
